Figure 1.

Adjusted predicted weight (kg) over time before and after TDF‐TAF switch among PLWH who maintained all other ARVs.

(A) Overall, (B) by core agent class. Estimated with linear mixed model with restricted cubic splines on time; reference: 45 years old non‐Black man, BMI: 27, CD4 cell count: 700, no endocrine disorder, no medications associated with weight gain/loss. ARV, antiretroviral; BMI, body mass index; PI, protease inhibitor; InSTI, integrase strand transfer inhibitor; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PLWH, people living with HIV; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.